Reversibility of experimental acute renal failure in rats: assessment with USPIO-enhanced MR imaging.
The purpose of this study was to evaluate the potential reversibility of kidney lesions in an experimental model of acute renal failure using ultra-small particles of iron oxide (USPIO)-enhanced magnetic resonance (MR) imaging. This study was conducted in 21 uninephrectomized rats using a model of iodinated contrast media-induced renal failure. Thirteen rats received selective intraarterial renal administration of diatrizoate (370 mg/ml) and were compared with two control groups, including six animals injected with saline and two noninjected animals. MR imaging was performed 28 hours, 8 days, and 22 days after the procedure. Each MR session included axial and coronal T1- and coronal T2-weighted images before and after intravenous administration of 60 micromol Fe/kg of USPIO. The rats were sacrificed immediately after the last MR session for pathologic evaluation. MR images were qualitatively and quantitatively interpreted with respect to pathologic data, and differences were statistically studied. At day 22, histology showed 4 severely diseased kidneys with focal areas of necrosis, 5 mildly diseased kidneys with tubular vacuolization, and 12 normal kidneys. On quantitative data, a high correlation between the percentage of negative enhancement and histologic data was observed (P < 0.05). Qualitative interpretation showed a sensitivity and specificity of USPIO-enhanced T2-weighted MR images of 88% and 91%, respectively. Follow-up enhancement curves showed a constant increase of intrarenal USPIO negative enhancement in normal kidneys between day 1 and day 22, whereas all severely involved kidneys displayed higher USPIO negative enhancement at day 1 without significant changes over time until day 22. USPIO may be useful for in vivo follow-up of the reversibility of experimentally induced iodinated contrast media renal impairment in animals.
Department of Radiology, Hôpital Bichat, Paris, France. jean-pierre.laissy@bch.ap-hop-paris.fr
J P
JP
Laissy
J M
JM
Idée
A
A
Loshkajian
S
S
Benderbous
S
S
Chillon
H
H
Beaufils
E
E
Schouman-Claeys
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000704:Analysis of Variance; D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D003911:Dextrans; D003973:Diatrizoate / Q000633:toxicity*; D052203:Ferrosoferric Oxide; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage; D016014:Linear Models; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D009392:Nephrectomy; D015588:Observer Variation; D010087:Oxides / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D012680:Sensitivity and Specificity
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D003973:Diatrizoate; D003404:Creatinine; D007501:Iron; D052203:Ferrosoferric Oxide